Stang Michael T, Yim John H, Challinor Sue M, Bahl Sachin, Carty Sally E
Department of Surgery, University of Pittsburg School of Medicine, PA 15261, USA.
Surgery. 2005 Dec;138(6):1058-64; discussion 1064-5. doi: 10.1016/j.surg.2005.09.011.
We hypothesized that hyperthyroidism after parathyroid exploration may be an underreported phenomenon with a course more severe than recognized previously.
We examined pre- and postoperative thyroid function and outcomes in 199 consecutive patients who, since March 2000, had parathyroid exploration for primary sporadic hyperparathyroidism (HPTH). We excluded patients with prior thyroid or parathyroid surgery, preoperative thyroid medication, concurrent total thyroidectomy, or follow-up <5 months.
Of 125 patients with normal preoperative serum thyroid-stimulating hormone levels, 39 (31.2%) were hyperthyroid postoperatively. Mean thyroid-stimulating hormone levels (mean +/- SD) dropped with operation from 2.0 +/- 1.1 microIU/mL to 1.2 +/- 1.4 microIU/mL (P < .0001). Nineteen patients (15%) reported symptoms 1 to 2 weeks after operation. The clinical course of hyperthyroidism typically was short, but 5 patients (4%) had symptomatic hyperthyroxinemia requiring medical therapy. Hyperthyroidism was independent of age, severity of HPTH, anatomic/pathologic features, operative time, and other measures of operative difficulty, but was associated with lithium therapy, bilateral exploration, and absence of concurrent thyroid lobectomy.
Risk of hyperthyroidism may be underappreciated after routine parathyroid surgery for HPTH. Use of lithium and degree of dissection appear contributory. Patients undergoing parathyroid exploration need counseling and surveillance for hyperthyroidism, which may be reduced by minimizing the extent of parathyroid surgery.
我们推测甲状旁腺探查术后发生的甲状腺功能亢进可能是一种未被充分报道的现象,其病程比之前认识到的更为严重。
我们检查了自2000年3月以来因原发性散发性甲状旁腺功能亢进(HPTH)接受甲状旁腺探查的199例连续患者的术前和术后甲状腺功能及结果。我们排除了既往有甲状腺或甲状旁腺手术史、术前使用甲状腺药物、同期行甲状腺全切除术或随访时间<5个月的患者。
在125例术前血清促甲状腺激素水平正常的患者中,39例(31.2%)术后发生甲状腺功能亢进。促甲状腺激素平均水平(均值±标准差)随手术从2.0±1.1微国际单位/毫升降至1.2±1.4微国际单位/毫升(P<.0001)。19例患者(15%)在术后1至2周报告有症状。甲状腺功能亢进的临床病程通常较短,但5例患者(4%)有症状性甲状腺素血症需要药物治疗。甲状腺功能亢进与年龄、HPTH的严重程度、解剖/病理特征、手术时间及其他手术难度指标无关,但与锂治疗、双侧探查及未同期行甲状腺叶切除术有关。
对于HPTH行常规甲状旁腺手术后甲状腺功能亢进的风险可能未得到充分认识。锂的使用和解剖范围似乎起了作用。接受甲状旁腺探查的患者需要接受关于甲状腺功能亢进的咨询和监测,通过尽量减少甲状旁腺手术范围可能会降低这种风险。